Stefan Hildbrand
Hoffmann-La Roche
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Stefan Hildbrand.
Journal of Medicinal Chemistry | 2008
Leo Alig; Jochem Alsenz; Mirjana Andjelkovic; Stefanie Bendels; Agnès Bénardeau; Konrad Bleicher; Anne Bourson; Pascale David-Pierson; Wolfgang Guba; Stefan Hildbrand; Dagmar Kube; Thomas Lübbers; Alexander V. Mayweg; Robert Narquizian; Werner Neidhart; Matthias Nettekoven; Jean-Marc Plancher; Cynthia Rocha; Mark Rogers-Evans; Stephan Röver; Gisbert Schneider; Sven Taylor; Pius Waldmeier
The application of the evolutionary fragment-based de novo design tool TOPology Assigning System (TOPAS), starting from a known CB1R (CB-1 receptor) ligand, followed by further refinement principles, including pharmacophore compliance, chemical tractability, and drug likeness, allowed the identification of benzodioxoles as a novel CB1R inverse agonist series. Extensive multidimensional optimization was rewarded by the identification of promising lead compounds, showing in vivo activity. These compounds reversed the CP-55940-induced hypothermia in Naval Medical Research Institute (NMRI) mice and reduced body-weight gain, as well as fat mass, in diet-induced obese Sprague-Dawley rats. Herein, we disclose the tools and strategies that were employed for rapid hit identification, synthesis and generation of structure-activity relationships, ultimately leading to the identification of (+)-[( R)-2-(2,4-dichloride-phenyl)-6-fluoro-2-(4-fluoro-phenyl)-benzo[1,3]dioxol-5-yl]-morpholin-4-yl-methanone ( R)-14g . Biochemical, pharmacokinetic, and pharmacodynamic characteristics of ( R)-14g are discussed.
Chimia | 2018
Dan Fishlock; Ralph Diodone; Stefan Hildbrand; Bernd Kuhn; Christian Mössner; Carsten Peters; Pankaj D. Rege; Gösta Rimmler; Markus Schantz.
A concise asymmetric synthesis has been developed to prepare idasanutlin, a small molecule MDM2 antagonist. Idasanutlin is currently being investigated as a potential treatment for various solid tumors and hematologic malignancies. The highly congested pyrrolidine core, containing four contiguous stereocenters, was constructed via a Cu(I)/(R)-BINAP catalyzed [3+2]-cycloaddition reaction. This optimized copper(I)-catalyzed process has been used to produce more than 1500 kg of idasanutlin. The manufacturing process will be described, highlighting the exceptionally selective and consistent cycloaddition/isomerization/hydrolysis sequence. The excellent yields, short cycle times and reduction in waste streams result in a sustainable production process with low environmental impact.
Archive | 2007
Stefan Abrecht; Jean-Michel Adam; Alec Fettes; Stefan Hildbrand
Archive | 2012
Stefan Hildbrand; Hans-Juergen Mair; Roumen Nikolaev Radinov; Yi Ren; James Anderson Wright
Archive | 2007
Peter John Harrington; Stefan Hildbrand; Keshab Sarma
Organic Process Research & Development | 2011
Stefan Abrecht; Jean-Michel Adam; Ulrike Bromberger; Ralph Diodone; Alec Fettes; Rolf Fischer; Volker Goeckel; Stefan Hildbrand; Gérard Moine; Martin Weber
Archive | 2008
Ulrike Bromberger; Ralph Diodone; Stefan Hildbrand; Roland Meier
Archive | 2006
Stefan Hildbrand; Bruno Lohri; Wolfgang Wostl
Organic Process Research & Development | 2016
Gösta Rimmler; André Alker; Marcello Bosco; Ralph Diodone; Dan Fishlock; Stefan Hildbrand; Bernd Kuhn; Christian Moessner; Carsten Peters; Pankaj D. Rege; Markus Schantz.
Archive | 2013
Robert Carr; Stefan Hildbrand; L. Mark Hodges; Michael Kammerer; John F. Lang; William J. Lawrimore; Dieu Nguyen